会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • A THERMAL DETECTOR
    • 一个热探测器
    • WO2007137995B1
    • 2008-03-20
    • PCT/EP2007055068
    • 2007-05-24
    • UNIV LIEGEFLEURY-FRENETTE KARLHABRAKEN SERGERENOTTE YVONHASTANIN JURIY
    • FLEURY-FRENETTE KARLHABRAKEN SERGERENOTTE YVONHASTANIN JURIY
    • G01J5/58G01J5/40
    • G01J5/58G01J5/40
    • A first object of the invention is a radiation detector comprising an energy absorber (203), for absorbing incident radiation (RAD) and thus undergoing a temperature increase; and optical readout means, for detecting said temperature increase; wherein said optical readout means comprises input coupling means (202) for coupling a light beam (2011) to said energy absorber (203) by exciting surface plasmons resonance, a surface plasmons resonance condition being dependent on the energy absorber (203) temperature, and wherein said energy absorber (203) is separated from said input coupling means (202) by a dielectric layer (2032). A second object of the invention is a micromechanical sensor comprising: a micromechanical oscillator and optical readout means (202) for detecting a displacement of said micromechanical oscillator; wherein said optical readout means comprise input coupling means (202) for coupling a light beam (2011) to a conductive surface (2031) by exciting surface plasmons resonance, a surface plasmons resonance condition being dependent on the displacement of said micromechanical oscillator.
    • 本发明的第一个目的是一种辐射探测器,其包括用于吸收入射辐射(RAD)并因此经历温度增加的能量吸收器(203) 和光学读出装置,用于检测所述温度升高; 其中所述光学读出装置包括用于通过激励表面等离子体激元共振(表面等离子体激元共振条件取决于能量吸收器(203)温度)将光束(2011)耦合到所述能量吸收器(203)的输入耦合装置(202) 其中所述能量吸收器(203)通过介电层(2032)与所述输入耦合装置(202)分离。 本发明的第二个目的是一种微机械传感器,包括:微机械振荡器和光学读出装置(202),用于检测所述微机械振荡器的位移; 其中所述光学读出装置包括用于通过激励表面等离子体激元共振而将光束(2011)耦合到导电表面(2031)的输入耦合装置(202),表面等离子体激元共振条件取决于所述微机械振荡器的位移。
    • 6. 发明申请
    • A METHOD FOR QUALITATIVE AND/OR QUANTITATIVE DETECTION OF POLYETHYLENE GLYCOLS IN BIOLOGICAL FLUIDS
    • 聚乙烯甘油在生物流体中定性和/或定量检测的方法
    • WO2005024423A3
    • 2005-06-23
    • PCT/EP2004051970
    • 2004-08-31
    • UNIV LIEGEGRANDFILS CHRISTIANDANDRIFOSSE GUYREMACLE RENEBARAKAT IBRAHIMDELOYER PATRICIA
    • GRANDFILS CHRISTIANDANDRIFOSSE GUYREMACLE RENEBARAKAT IBRAHIMDELOYER PATRICIA
    • G01N31/22G01N33/52
    • G01N33/52G01N31/22
    • The subject matter of the present invention relates a method for detection of polyethylene glycols (PEG) in an aqueous solution or in a sample of a biological fluid in a qualitative and/or semi-quantitative and/or quantitative manner, the method comprising the addition of a reagent containing iodine, alkali metal iodide and an acid; and a method for assessing the permeability of the intestine wherein two PEGs of different molecular weight, low molecular weight PEG (l.m.w. PEG) and high molecular weight PEG (h.m.w. PEG) are used as markers, wherein the l.m.w. PEG is able to cross the intestinal mucosa under physiological conditions and the h.m.w. PEG is essentially not able to cross the intestinal mucosa under physiological conditions, but is able to cross the intestinal mucosa under non-physiological, irregular conditions; and wherein h.m.w. and l.m.w. PEG concentrations are measured in a sample of urine from an individual after oral administration of h.m.w. PEG and l.m.w. PEG, wherein the differential index of h.m.w. PEG and l.m.w. PEG in the urine is calculated after determining the concentrations of h.m.w. PEG and l.m.w. PEG by using a reagent for quantitative detection of polyethylene glycol (PEG) in biological fluids, the reagent containing iodine, alkali metal iodide and an acid; and a kit for qualitative and/or semi-quantitative and/or quantitative detection of polyethylene glycol in biological fluids, e.g. in urine.
    • 本发明的主题涉及以定性和/或半定量和/或定量方式在水溶液或生物流体样品中检测聚乙二醇(PEG)的方法,所述方法包括添加 含有碘,碱金属碘化物和酸的试剂; 和用于评估肠的渗透性的方法,其中使用不同分子量的低分子量PEG(1m.w.PEG)和高分子量PEG(h.m.w.PEG)的两种PEG作为标记物,其中l.m.w. PEG在生理条件下能够穿过肠粘膜,而h.m.w. PEG在生理条件下基本上不能穿过肠粘膜,但能够在非生理,不规则的条件下穿过肠粘膜; 并且其中h.m.w 和l.m.w. 在口服h.m.w后,来自个体的尿液样品中测量PEG浓度。 PEG和l.m.w. PEG,其中h.m.w的微分指数 PEG和l.m.w. 在确定h.m.w的浓度后计算尿中的PEG。 PEG和l.m.w. PEG通过使用用于在生物体液中定量检测聚乙二醇(PEG)的试剂,含有碘,碱金属碘化物和酸的试剂; 以及用于生物流体中聚乙二醇的定性和/或半定量和/或定量检测的试剂盒,例如。 在尿液
    • 7. 发明申请
    • DETECTION METHOD BY PCR
    • PCR检测方法
    • WO0131056A3
    • 2002-06-27
    • PCT/BE0000131
    • 2000-10-27
    • UNIV LIEGEZORZI WILLYMELEN LAURENCEZORZI DANIELEEL MOUALIJ BENAISSAHEINEN ERNST
    • ZORZI WILLYMELEN LAURENCEZORZI DANIELEEL MOUALIJ BENAISSAHEINEN ERNST
    • C12Q1/68G01N33/50G01N33/543
    • C12Q1/686C12Q1/6804
    • The invention concerns a method using PCR, in particular immuno-PCR, for detecting microbiological entities and in particular elements or target molecules. The detection method comprises a step which consists in fixing an entity A, more particularly an antigen, directly or via a capture agent, for example an antibody, to one or several surface(s) inside the receptacle(s) of a real time PCR measuring apparatus and a step which consists in associating with said element A a coupling system with a nucleic acid, for example a DNA marker, a step which consists in amplifying the marker nucleic acid. The successive measurements are carried out during the phase amplifying the marker nucleic acid, in the presence of a capture agent and other optional intermediate fixing agents. The detection method is quantitative and can be used in particular for prion polypeptide assay.
    • 本发明涉及使用PCR,特别是免疫PCR的方法来检测微生物实体,特别是元件或靶分子。 检测方法包括将实体A,特别是抗原直接或经由捕获剂(例如抗体)固定在实时PCR中的一个或多个容器内的一个或多个表面的步骤 测量装置和步骤,其包括与所述元件A结合与核酸(例如DNA标记)的偶联系统,其包含扩增标记核酸的步骤。 在捕获剂和其它任选的中间固定剂的存在下,在标记核酸的相扩增期间进行连续的测量。 检测方法是定量的,可以特别用于朊病毒多肽测定。
    • 8. 发明申请
    • A MONOMODE OPTICAL FIBRE
    • 单色光纤
    • WO0223236A3
    • 2002-06-06
    • PCT/EP0110549
    • 2001-09-12
    • UNIV LIEGE
    • LEMAIRE PHILIPPESCAUFLAIRE VERONIQUE
    • G02B6/02G02B6/036G02B6/24G02B6/26G02B6/44G02B6/22G02B6/16
    • G02B6/03627G02B6/241G02B6/262G02B6/4402G02B6/4478
    • A monomode optical fibre provided for transporting light having a wavelength comprised between 480 and 550 nm. The fibre comprises a core made of a first transparent dielectric material having a first refractive index nc and a substantially circular cross-section with a radius dimension a. The fibre further comprises a first cladding coaxially applied on said core and made of a second transparent dielectric material having a second refractive index nm1 inferior to nc. The first transparent dielectric material consists in substantially pure silica, the second transparent dielectric material consists in doped silica, the thickness of the first cladding is comprised in a range of 5 to 15 microns and the values of nc and nm1 are choosen in such a manner that the numerical aperture is less than 0.1 and the radius dimension a is above 2 microns.
    • 提供用于传输波长在480和550nm之间的光的单模光纤。 纤维包括由具有第一折射率nc的第一透明介电材料制成的芯和具有半径尺寸a的基本圆形的横截面。 纤维还包括同轴施加在所述芯上并由具有低于nc的第二折射率nm1的第二透明电介质材料制成的第一包层。 第一透明介电材料由基本上纯的二氧化硅组成,第二透明介电材料由掺杂的二氧化硅组成,第一包层的厚度在5至15微米的范围内,并且以这种方式选择nc和nm1的值 数值孔径小于0.1,半径尺寸a大于2微米。
    • 10. 发明申请
    • ANTIANGIOGENIC PEPTIDES
    • 抗血管生成肽
    • WO2006018418A3
    • 2006-08-10
    • PCT/EP2005053952
    • 2005-08-11
    • UNIV LIEGEGEMBLOUX FACULTE UNIVERSITAIREMARTIAL JOSEPHSTRUMAN INGRIDNGUYEN NGOC-QUYNH-NHUBRASSEUR ROBERTLINS LAURENCE
    • MARTIAL JOSEPHSTRUMAN INGRIDNGUYEN NGOC-QUYNH-NHUBRASSEUR ROBERTLINS LAURENCE
    • C07K14/61A61K38/16A61K38/22A61K38/39A61P43/00C07K14/155C07K14/47C07K14/575C07K14/78
    • C07K14/005A61K38/00C07K14/47C07K14/4711C07K14/57518C07K14/57554C07K14/61C07K14/78C12N2740/15022
    • The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, lle, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: lle, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, lle, Val; X7 is an amino acid residue of: Leu, lle, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, lle, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.
    • 本发明涉及包含分离的抗血管生成肽或包含抗血管生成肽的重组蛋白的药物组合物,其中所述肽的长度在11至40个氨基酸之间并且具有抗血管生成活性,所述肽包含氨基酸序列:X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14,其中X1是与形成螺旋相容的任何氨基酸残基; X2是以下氨基酸残基:Leu,Ile,Val; X3是Arg,Lys,His,Ser,Thr的氨基酸残基; X4是Ile,Leu,Val的氨基酸残基; X5是与形成螺旋相容的任何氨基酸残基; X6是Leu,Ile,Val的氨基酸残基; X7是Leu,Ile,Val,Ser,Thr的氨基酸残基; X8是与形成螺旋相容的任何氨基酸残基; X9是与形成螺旋相容的任何氨基酸残基; X10是Gln,Glu,Asp,Arg,His,Lys,Asn的氨基酸残基; X11是Ser,Thr的氨基酸残基; X12是Trp,Tyr,Phe的氨基酸残基; X13是Leu,Ile,Val,Asn,Gln的氨基酸残基; X14是Glu,Gln,Asp,Asn的氨基酸残基。